Theriva^™ Biologics Announces Key Progress in VIRAGE, an Ongoing, Multinational Phase IIb Trial of VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma

Theriva™ Biologics announced key progress in VIRAGE, a multinational, Phase IIb, randomized, open-label, controlled clinical trial evaluating VCN-01 in combination with standard-of-care chemotherapy as a first-line therapy for patients with metastatic PDAC.